Interview: Lee-Cheng Liu, President & CEO, EirGenix, Taiwan
Dr. Liu, President and CEO of EirGenix, talks about why he sees Taiwan as the ideal market for a CDMO like Eirgenix, why he believes that despite the skepticism, biosimilars…
Address: 11F, 80 Linshen North Road, Taipei,Taiwan
Tel: (02)2655-8168
Web: http://www.ibmi.org.tw/client/
The Institute for Biotechnology and Medicine Industry (IBMI) is a non-profit organization registered with the relevant authorities of Taiwan. Supported by the President of Legislative Yuan, Mr. Wang Jin-Pyng, the predecessor of IBMI began its operation in 1998. In 1999, Mr. Wang took on the post as the chairman and defined the mission of IBMI as ‘Upgrading Biotechnology and Medicine for National Health’. In March 2002, IBMI was officially founded as an organization dedicated to promoting the biotechnology and medicine industry. In June 2005, IBMI convened its first member conference of the second year where the second board of directors and supervisors were elected. The board continued to uphold the ideology and mission of the organization to push forward industrial growth. In May 2009, at the first member conference of the third year the third board of directors and supervisors were elected. Mr. Wang Jin-Pyng was unanimously honored as the founder of IBMI and for his contribution to the biotechnology and medicine industry. Former President of National Taiwan University and the Vice Chairman of IBMI, Dr. Chen Wei-Zhao was elected as chairman of the third board of directors and supervisors to lead IBMI.
The mission of IBMI is to best utilize the collective public and private resources for successfully developing Taiwan’s biomedical industry, specifically, to establish platforms for biomedical industrial cooperation and resource sharing in order to achieve goals concerning biomedical technology and its commercialization, healthcare and healthcare service, and social welfare.
From perspective of policy development, at IBMI, it is considered that productive industry policy and market mechanism are essential for assuring the best interest of the state and the public. Innovation-based approaches to developing the emerging industry and market-oriented approaches to commercialization are keys to improving state’s economic competitiveness. Therefore, IBMI intends to assist government and industry in formulating and implementing relevant industrial policies, establishing market mechanism, fostering innovation, and ensuring global competitiveness.
Based on the above considerations, IBMI sets its priority to cause productive partnerships among academia, government, industry and research institutions. Therefore, through promotion and operation of its six functions, i.e., ‘Productive Legislation and Policies’, ‘Certification and Market Mechanism’, ‘Education and Training’, ‘Bioinformatics and Bio-trading’, ‘Advanced and Applied Bio-researches’, and ‘Emerging Business Development’, IBMI strives to develop Taiwan’s biomedical industry, improve the quality of its healthcare system, as well as enhance its overall competitiveness.
The Institute for Biotechnology and Medicine Industry (IBMI) is a non-profit organization registered with the relevant authorities of Taiwan.The mission of IBMI is to best utilize the collective public and private resources for successfully developing Taiwan’s biomedical industry, specifically, to establish platforms for biomedical industrial cooperation and resource sharing in order to achieve goals concerning biomedical technology and its commercialization, healthcare and healthcare service, and social welfare.
Dr. Liu, President and CEO of EirGenix, talks about why he sees Taiwan as the ideal market for a CDMO like Eirgenix, why he believes that despite the skepticism, biosimilars…
Whaijen Soo, Managing Director of Supra Integration and Incubation Center (Si2C) speaks about Taiwan’s biotech industry, emphasizing the need for risk tolerance and understanding investing rationale in propelling Taiwan’s industry…
Audrey Tseng, Deputy Chairman of PwC Taiwan with PwC Partners Lily Wong and Andy Chang, delve into factors behind the booming pharma and biotech industry in Taiwan, how to prevent…
Dr Yu-Ray Chen, Professor of Surgery at Chang Gung Memorial Hospital discusses the current state of Taiwan’s healthcare system, highlighting the fact that its current condition is unsustainable in the…
Michael Chiang, the Executive President of Panion & BF Biotech speaks about the incredible growth of the company over the past year, what has contributed to this success and where…
James Wang, Country Managing Partner of Ernst & Young Taiwan explains why Taiwan’s DIG (Diversify-Innovative-Globalize) strategy is crucial for the growth of Taiwan’s economy over the next decade, why biotech…
Full service CRO Choice Pharma moved its operations from Europe to Asia in 2008, and since then the company has thrived. The managing director and business director for the company…
A 2006 article in CommonWealth Magazine detailing the genesis of this company reported that TLC had managed to “break out from the typical dilemma of ordinary biotech firms—to either engage…
The president of Pharmaceutical Industry Technology and Development Center (PITDC) considers the company’s need to remain an international competitor and how to achieve it, the gap in new drug development…
General Manager, Chugai Pharma Taiwan and President of International Research-Based Pharmaceutical Manufacturers’ Association (IRPMA), discusses the continuous price cuts that plague the Taiwan market, and how IRPMA is getting involved…
The CEO of ASLAN Pharmaceuticals discusses the fundamental changes that need to occur in the treatment of serious illnesses, the advantages of building a second branch in Taiwan, and the…
The chairman of Taipei Medical University (TMU) discusses the key challenges TMU has faced over the years, how these challenges will continue to affect the future, and what international accreditation…
See our Cookie Privacy Policy Here